hepatotoxicity found that the labeling was highly variable and was affected by multiple factors, including recommendations made by different FDA drug review committees. In comparing
drug labels with strategies for laboratory monitoring for hepatotoxicity, 12 different schedules were given for 15 drugs.23
Based on two national physician surveys, the FDA has recognized
the need for revising the label format, and in June 2006 began a process to prioritize the positioning of information on the label. This includes placing the black box warning at the front of the prescribing information.24
